Influenza viruses circulate globally and affect all age groups. Vaccines are the best tools available for preventing influenza illness and are recommended annually by the World Health Organization (WHO). The ability of the influenza virus to change its structure results in the generation of a new influenza type, to which a large proportion of the human population has no pre-existing immunity. We are developing an Influenza vaccine using a new method of manufacture.
The vaccine is created to produce Influenza-like proteins. This method of vaccine production is able to provoke a strong immune response, and it is hoped that your body will produce the protective blood proteins called antibodies that will protect you from Influenza infection.
Unlike current flu vaccines which are formulated annually to protect against specific new flu virus strains, this new vaccine is designed to protect against a large range of flu viruses and will not need to be changed each year.
Previous studies have shown the vaccine to be well tolerated, able to improve protection against a range of virus strains and reduce the severity of flu symptoms, when tested alone in a small group of healthy volunteers.
If you take part in the study you will receive either the study vaccine or placebo (does not contain active ingredients) in addition to the licensed flu vaccine, if you have not received the licensed flu vaccine within 28 days prior to study enrolment.
If you meet the criteria for this study and would like more information, register below or call 1800 727 874